Brokers Offer Predictions for Korro Bio FY2025 Earnings

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Korro Bio in a report released on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse expects that the company will earn ($8.91) per share for the year. Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Korro Bio's current full-year earnings is ($9.52) per share.

A number of other equities analysts also recently issued reports on the company. Chardan Capital began coverage on Korro Bio in a research report on Wednesday, April 16th. They set a "buy" rating and a $25.00 price target on the stock. Royal Bank of Canada dropped their price objective on shares of Korro Bio from $105.00 to $95.00 and set an "outperform" rating on the stock in a research note on Wednesday, March 19th. HC Wainwright restated a "buy" rating and set a $115.00 target price on shares of Korro Bio in a report on Thursday, March 20th. Finally, Oppenheimer initiated coverage on Korro Bio in a research report on Friday, January 10th. They issued an "outperform" rating and a $155.00 price target for the company. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Korro Bio has a consensus rating of "Buy" and an average price target of $114.63.

Korro Bio Price Performance

Shares of NASDAQ:KRRO traded down $2.54 during trading on Thursday, reaching $15.13. 52,687 shares of the company were exchanged, compared to its average volume of 96,867. The firm has a market capitalization of $142.09 million, a PE ratio of -1.61 and a beta of 2.66. The business's fifty day simple moving average is $18.48 and its 200-day simple moving average is $35.64. Korro Bio has a 12-month low of $11.13 and a 12-month high of $98.00.

Korro Bio (NASDAQ:KRRO - Get Free Report) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($2.26) earnings per share for the quarter, topping the consensus estimate of ($2.33) by $0.07. The business had revenue of $2.27 million during the quarter.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new stake in Korro Bio in the fourth quarter valued at approximately $53,000. AlphaQuest LLC increased its holdings in Korro Bio by 23.2% in the 4th quarter. AlphaQuest LLC now owns 2,189 shares of the company's stock worth $83,000 after acquiring an additional 412 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Korro Bio by 32.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,392 shares of the company's stock valued at $129,000 after purchasing an additional 831 shares in the last quarter. Deutsche Bank AG increased its stake in shares of Korro Bio by 29.4% during the fourth quarter. Deutsche Bank AG now owns 4,110 shares of the company's stock worth $156,000 after purchasing an additional 935 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in Korro Bio by 664.1% in the 4th quarter. Legal & General Group Plc now owns 4,325 shares of the company's stock valued at $165,000 after buying an additional 3,759 shares in the last quarter. 13.18% of the stock is currently owned by hedge funds and other institutional investors.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).